Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stated that, subsequent to an autonomous DSMB recommendation and also following futility assessment, it has halted the Phase II HERMIONE trial of “MM-302” in people suffering with +HER2 metastatic breast cancer, but had initially been on regimen of pertuzumab, trastuzumab and ado-trastuzumab emtansine. The buzz The decision...
Heat Biologics Inc (NASDAQ:HTBX) recently said that the survival results and top-line response of Phase 1b study evaluating lung cancer treatment with Bristol-Myers Squibb’s drug showed positive signs. The company reported HS-110/Nivolumab Combination for treating non-small cell lung cancer (NSCLC) in Austria at International Association for the Study of...
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) inked an alliance agreement with Novartis for development of their lead product, a drug called emricasan. The transaction was done with an upfront cost of $50 million and around $650 million to be paid in milestone payments in the times to come. Novartis gets emricasan’s rights...
Aducanumab, a clinical treatment drug, primed to treat those with early symptoms of Alzheimer’s, recently went into Phase 1B clinical studies trial. Recently, the firm responsible for the manufacturing of the clinical treatment drugs, Biogen Inc. (NASDAQ:BIIB) released the data obtained from the Phase 1B trial. The data will be...
May 06, 2015 OTC Disclosure & News Service - SILVER SPRING, Md., May 6, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Institute of Virology at the...
Dallas, Texas 04/28/2014 (FINANCIALSTRENDS) – Prana Biotechnology Limited (ADR)(NASDAQ:PRAN) has in the past week announced the results of the top-line results after the company declared its ‘12-month Phase II imaging trails’ as part of its Alzheimer’s disease solution matrix. With several companies vying for top drug or therapy to resolve age-related problems...
Dallas, Texas 04/03/2014 (FINANCIALSTRENDS) – iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) has been on the top for quite a long time now and recently has taken a U-turn and is heading on a downward spiral. This sudden fall was seen after 17th March when the Democrats' who were attending the...
Dallas, Texas 09/16/2013 (Financialstrend) - In a research note that was issued on Thursday, Needham & Company weighed on Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) stock. They have assigned a “buy” rating on the stock and a price-target of $8.00. This price-target is an indication that there is a potential upside...

Subscribe to our mailing list

* indicates required

Create a future where the human body can repair, restore, and rejuvenate itself

 

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Play